# Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

> **NCT02273661** · PHASE2 · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 174 (actual)

## Conditions studied

- Allergic Bronchopulmonary Aspergillosis

## Interventions

- **DRUG:** Liposomal amphotericin B (Ambisome®)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02273661
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-19
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273661, "Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02273661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*